Accumulation of major linezolid metabolites in patients with renal impairment

Ernane Souza; Ryan L. Crass; Jeremy Felton; Kengo Hanaya; Manjunath P. Pai

doi:10.1128/AAC.00027-20

Accumulation of major linezolid metabolites in patients with renal impairment

Ernane Souza, Ryan L. Crass, Jeremy Felton, Kengo Hanaya, Manjunath P. Pai

薬科学科

研究成果: Article › 査読

14 被引用数 (Scopus)

抄録

In patients with renal impairment (n=22 of 39), the median serum concentrations of linezolid, PNU-142300, and PNU-142586 were 1.6-, 3.3-, 2.8-fold higher, respectively, than in patients without renal impairment. Metabolite concentrations in paired samples were poorly correlated with linezolid concentrations (r² = 0.26 for PNU-142300 and 0.06 for PNU-142586). Linezolid and its metabolites share potential toxicophores that deserve characterization to mitigate higher myelosuppression risk in patients with renal impairment.

本文言語	English
論文番号	e00027-20
ジャーナル	Antimicrobial Agents and Chemotherapy
巻	64
号	5
DOI	https://doi.org/10.1128/AAC.00027-20
出版ステータス	Published - 2020 5月 1

ASJC Scopus subject areas

薬理学
薬理学（医学）
感染症

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1128/AAC.00027-20

他のファイルとリンク

引用スタイル

@article{c7bbede5a30746b49e61cfa883cfadd2,

title = "Accumulation of major linezolid metabolites in patients with renal impairment",

abstract = "In patients with renal impairment (n=22 of 39), the median serum concentrations of linezolid, PNU-142300, and PNU-142586 were 1.6-, 3.3-, 2.8-fold higher, respectively, than in patients without renal impairment. Metabolite concentrations in paired samples were poorly correlated with linezolid concentrations (r2 = 0.26 for PNU-142300 and 0.06 for PNU-142586). Linezolid and its metabolites share potential toxicophores that deserve characterization to mitigate higher myelosuppression risk in patients with renal impairment.",

keywords = "Dialysis, Myelosuppression, Oxazolidinones, Pharmacodynamics, Toxicology",

author = "Ernane Souza and Crass, {Ryan L.} and Jeremy Felton and Kengo Hanaya and Pai, {Manjunath P.}",

note = "Funding Information: This study was supported through start-up funds from the University of Michigan to M.P.P. We have no conflicts of interest to declare. Publisher Copyright: {\textcopyright} 2020 American Society for Microbiology. All Rights Reserved.",

year = "2020",

month = may,

day = "1",

doi = "10.1128/AAC.00027-20",

language = "English",

volume = "64",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "5",

}

TY - JOUR

T1 - Accumulation of major linezolid metabolites in patients with renal impairment

AU - Souza, Ernane

AU - Crass, Ryan L.

AU - Felton, Jeremy

AU - Hanaya, Kengo

AU - Pai, Manjunath P.

N1 - Funding Information: This study was supported through start-up funds from the University of Michigan to M.P.P. We have no conflicts of interest to declare. Publisher Copyright: © 2020 American Society for Microbiology. All Rights Reserved.

PY - 2020/5/1

Y1 - 2020/5/1

N2 - In patients with renal impairment (n=22 of 39), the median serum concentrations of linezolid, PNU-142300, and PNU-142586 were 1.6-, 3.3-, 2.8-fold higher, respectively, than in patients without renal impairment. Metabolite concentrations in paired samples were poorly correlated with linezolid concentrations (r2 = 0.26 for PNU-142300 and 0.06 for PNU-142586). Linezolid and its metabolites share potential toxicophores that deserve characterization to mitigate higher myelosuppression risk in patients with renal impairment.

AB - In patients with renal impairment (n=22 of 39), the median serum concentrations of linezolid, PNU-142300, and PNU-142586 were 1.6-, 3.3-, 2.8-fold higher, respectively, than in patients without renal impairment. Metabolite concentrations in paired samples were poorly correlated with linezolid concentrations (r2 = 0.26 for PNU-142300 and 0.06 for PNU-142586). Linezolid and its metabolites share potential toxicophores that deserve characterization to mitigate higher myelosuppression risk in patients with renal impairment.

KW - Dialysis

KW - Myelosuppression

KW - Oxazolidinones

KW - Pharmacodynamics

KW - Toxicology

UR - http://www.scopus.com/inward/record.url?scp=85083681190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85083681190&partnerID=8YFLogxK

U2 - 10.1128/AAC.00027-20

DO - 10.1128/AAC.00027-20

M3 - Article

C2 - 32152085

AN - SCOPUS:85083681190

SN - 0066-4804

VL - 64

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 5

M1 - e00027-20

ER -

Accumulation of major linezolid metabolites in patients with renal impairment

抄録

ASJC Scopus subject areas

UN SDG

文献へのアクセス

他のファイルとリンク

フィンガープリント

引用スタイル